Abstract: The present disclosure provides ex vivo methods which employ modified cells of leukemic origin to enhance the efficacy of adoptive cell therapy with natural killer (NK) cells.

Abstract: Composition and methods for ex vivo expansion of natural killer (NK) cells, and methods for cell-based cancer immunotherapy are disclosed. Leukemic cell-derived dendritic cells and anti-PD-L1 antibodies, and certain embodiments with addition of PBMCs are used for in vivo administration for cancer treatment. Leukemic cell-derived dendritic cells and anti-PD-L1 antibodies are also used for ex vivo expansion of NK cells.

Abstract: Disclosed is a pro-inflammatory dendritic cell with improved ability to activate allo-geneic T-cells through the direct pathway of allorecognition. The dendritic cell is infected with an adenovirus. Further, the pro-inflammatory dendritic cell has been obtained by: —providing an immature dendritic cell; —infecting the dendritic cell with an adenovirus; and —maturating the immature dendritic cell into a pro-inflammatory dendritic cell by addition of the Toll-like receptor 3 (TLR3)-ligand poly-I:C, a TLR7/8-ligand, such as Resiquimod, and interferon gamma (IFN-?) to induce maturation of the immature dendritic cell.

Abstract: Disclosed is a method of producing non-exhausted immature dendritic cells (DCs) originating front at two different, allogeneic donors. In the method, a mixture of allogeneic leukocytes, which allogeneic leukocytes have been obtained from at least two different, allogeneic donors is provided. Subsequently, allogeneic monocytes are isolated from the mixture of allogeneic leukocytes. Thereafter, non-exhausted immature DCs are generated from said isolated allogeneic monocytes.

Abstract: The present invention relates to an in vitro method for priming T cells suitable for administration to a patient having a viral infection. The invention is also directed to the composition obtained by the method and uses thereof.

Abstract: Disclosed is a method of producing non-exhausted immature dendritic cells (DCs) originating front at two different, allogeneic donors. In the method, a mixture of allogeneic leukocytes, which allogeneic leukocytes have been obtained from at least two different, allogeneie donors is provided. Subsequently, allogeneic monocytes are isolated from the mixture of allogeneic leukocytes. Thereafter, non-exhausted immature DCs are generated from said isolated allogeneic monocytes.

Abstract: The present invention relates to an in vitro method for priming genetically modified T cells suitable for administration to a patient having a tumor. The invention is also directed to the composition obtained by the method and uses thereof.

Abstract: Disclosed is a method of producing non-exhausted immature dendritic cells (DCs) originating from at two different, allogeneic donors. In the method, a mixture of allogeneic leukocytes, which allogeneic leukocytes have been obtained from at least two different, allogeneic donors is provided. Subsequently, allogeneic monocytes are isolated from the mixture of allogeneic leukocytes. Thereafter, non-exhausted immature DCs are generated from said isolated allogeneic monocytes.

Abstract: The present invention relates to an in vitro method for priming T cells suitable for administration to a patient having a viral infection. The invention is also directed to the composition obtained by the method and uses thereof.

Abstract: The present invention relates to an in vitro method for priming genetically modified T cells suitable for administration to a patient having a tumor. The invention is also directed to the composition obtained by the method and uses thereof.

Abstract: The present invention relates to an in vitro method for priming T cells suitable for administration to a patient having a viral infection. The invention is also directed to the composition obtained by the method and uses thereof.

Abstract: The present invention relates to an in vitro method for priming genetically modified T cells suitable for administration to a patient having a tumor. The invention is also directed to the composition obtained by the method and uses thereof.

Abstract: The present invention relates to an in vitro method for priming T cells suitable for administration to a patient having a tumor. The invention is also directed to the composition obtained by the method and uses thereof.

Abstract: Disclosed is a method of producing non-exhausted immature dendritic cells (DCs) originating from at two different, allogeneic donors. In the method, a mixture of allogeneic leukocytes, which allogeneic leukocytes have been obtained from at least two different, allogeneic donors is provided. Subsequently, allogeneic monocytes are isolated from the mixture of allogeneic leukocytes. Thereafter, non-exhausted immature DCs are generated from said isolated allogeneic monocytes.

Abstract: This invention pertains to cancer immunotherapy, by providing a proinflammatory dendritic cell (DC), which has been stimulated to maturation ex vivo by specific treatment, a method for such treatment and a composition comprising the proinflammatory DC. The DC may be used as a cell based immunotherapy for inhibiting tumor cell proliferation.

Abstract: The present invention relates to a method for the production of a cellular allogeneic vaccine, which is based upon an allogeneic APC, comprising the following steps: isolation of an APC from a subject or providing an APC already established and/or isolated from a myeloid leukemia cell line, and modifying the APC with an antigen using any of the following methods: pulsing, transfection, infection or fusion; treatment using an agent capable of removing sialic acid on cell surfaces; and optionally culturing the APC in a suitable medium, an allogeneic vaccine obtainable by the above method, a composition comprising said vaccine and a pharmaceutically acceptable carrier and therapeutic use of said vaccine or said composition.

Abstract: The present invention relates to an in vitro method for priming genetically modified T cells suitable for administration to a patient having a tumor. The invention is also directed to the composition obtained by the method and uses thereof.

Abstract: The present invention relates to an in vitro method for priming T cells suitable for administration to a patient having a viral infection. The invention is also directed to the composition obtained by the method and uses thereof.

Abstract: The present invention relates to a method for the production of a cellular allogeneic vaccine, which is based upon an allogeneic APC, comprising the following steps: isolation of an APC from a subject or providing an APC already established and/or isolated from a myeloid leukemia cell line, and modifying the APC with an antigen using any of the following methods: pulsing, transfection, infection or fusion; treatment using an agent capable of removing sialic acid on cell surfaces; and optionally culturing the APC in a suitable medium, an allogeneic vaccine obtainable by the above method, a composition comprising said vaccine and a pharmaceutically acceptable carrier and therapeutic use of said vaccine or said composition.

Abstract: Microparticles are disclosed which comprise a bead essentially consisting of a cross-linked carbohydrate and an antigen covalently linked thereto. The microparticle can be used for the treatment of disorders of the immune system and in diagnostic tests.